LAVA Therapeutics NV - LVTX Net earnings per share for the last four quarters

Official company branding of Lava Tx (LVTX)

LAVA Therapeutics N.V. (LVTX) is aggressively competing for leadership in the bispecific antibody segment, attracting strategic partners to bypass pricing conflicts. This asset price chart helps track EPS dynamics, which currently stand at 16.50. The brand is renowned for the precision impact of its gamma-delta T-cell methods on solid tumors. Furthermore, ownership of the Gammabody system allows the company to establish favorable licensing terms for the market's largest players.

LAVA Therapeutics (LVTX) Earnings per share for the last twelve months: for the period 02/11/2024 - 12/06/2025

LVTX (LAVA Therapeutics NV): analytical breakdowns and indicator data

Initial company analysis:LVTX, LAVA Therapeutics N.V.
Mass-produced product of LAVA Therapeutics

This indicator measures the rate of change in net earnings per share over the last twelve months relative to the same period last year, reflecting the actual speed of business scaling. By analyzing the annual shift in EPS TTM, an investor assesses the commercialization efficiency of LAVA Therapeutics N.V. (LVTX) bispecific antibodies, where growth in this metric confirms the overcoming of molecular engineering complexities and successful navigation of FDA filters.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months